Expertise in
7
conditions

Montserrat Arnan

Barcelona, CT, ES 
Expertise in
7
conditions
Barcelona, CT, ES 

Overview

Montserrat Arnan practices practicing medicine in Barcelona, Spain.

Ms. Arnan is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Febrile Neutropenia, Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Barcelona, CT, Spain
Other Locations
Madrid, MD, Spain
L'hospitalet De Llobregat, CT 08908, Spain
Badalona, CT, Spain
Hospitalet Del Llobregat, Spain
Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drugs: Pevonedistat, Azacitidine
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients
Enrollment Status: Unknown
Publish Date: March 14, 2022
Intervention Type: Drug
Study Drugs: Quizartinib, Fludarabine, Cytarabine, Idarubicin, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

76 Total Publications

Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".
Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".
Journal: Antimicrobial agents and chemotherapy
Published: July 15, 2026

Frequently Asked Questions about Montserrat Arnan

Is Montserrat Arnan a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Montserrat Arnan is classified as an Distinguished expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Montserrat Arnan participate in research or clinical trials?

Yes. Montserrat Arnan has published 76 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Montserrat Arnan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Arnan's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile